



Quintiles Limited
The Pyramids Business Park
Easter Inch
Bathgate
WEST LOTHIAN
EH48 2EH
01506 818000/Fax 01506 814599

Clinical Trials Unit,
Medicines & Healthcare products Regulatory Agency
Market Towers,
1 Nine Elms Lane,
London.
SW8 5NQ

05 Dec 2008

Dear Sir/Madam

Re: A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminial (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson's Disease.

EudraCT Number: 2007-006721-27

Protocol number: CERE-120-06

MHRA Reference: 33823/0001/001-0001

Herewith, on behalf of Ceregene, Inc., we officially submit an End of Trial Notification for the above trial.

Please find enclosed a CD-ROM comprising the following documents:

- Cover Letter
- End of Trial Notification
- Withdrawal Statement from Ceregene, Inc.

We trust that the information provided in the notification is sufficient, however if you require any further information, please do not hesitate to contact me on [REDACTED]

Yours sincerely

[REDACTED]
Regulatory Affairs Officer
Quintiles Ltd

Ceregene

05 Dec 2008